Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR37X8)

• Drug Name: TTP-448 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMR37X8

Molecule-Related Drug Atlas

Drug(s) Targeting Advanced glycosylation end product receptor (AGER)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyridoxamine	DMVDCGZ	Diabetic kidney disease	GB61.Z	Phase 3	[3]
PF-4494700	DMJ7IKW	Alzheimer disease	8A20	Phase 3	[2]
Alagebrium chloride	DMD741P	Hypotension	BA20-BA21	Phase 2/3	[4]
TTP-4000	DMCG01R	Alzheimer disease	8A20	Phase 1	[5]
DBT-066	DMFYCQ1	Dementia	6D80-6D86	Investigative	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Advanced glycosylation end product receptor (AGER)	TTMO9HF	RAGE_HUMAN	Modulator	[2]

References

• [1] Biopharmaceutical Research Companies are Developing Nearly 100 Medicines for Alzheimer's Disease and Other Dementias. Pharmaceutical Research and Manufacturers of America report. 2012.
• [2] Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9.
• [3] Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010 Sep;17(9):1177-81.
• [4] Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage. Trans Am Ophthalmol Soc. 2009 Dec;107:146-58.
• [5] Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol. 2009; 4(2): 167-177.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2843).